image
Healthcare - Biotechnology - NASDAQ - US
$ 274.555
-1.37 %
$ 35.7 B
Market Cap
-128.48
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one ALNY stock under the worst case scenario is HIDDEN Compared to the current market price of 275 USD, Alnylam Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one ALNY stock under the base case scenario is HIDDEN Compared to the current market price of 275 USD, Alnylam Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one ALNY stock under the best case scenario is HIDDEN Compared to the current market price of 275 USD, Alnylam Pharmaceuticals, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ALNY

image
$300.0$300.0$290.0$290.0$280.0$280.0$270.0$270.0$260.0$260.0$250.0$250.0$240.0$240.0$230.0$230.0$220.0$220.015 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '25
FINANCIALS
2.25 B REVENUE
22.97%
-177 M OPERATING INCOME
37.31%
-278 M NET INCOME
36.82%
-8.31 M OPERATING CASH FLOW
-7.98%
-117 M INVESTING CASH FLOW
65.26%
294 M FINANCING CASH FLOW
70.89%
594 M REVENUE
0.17%
18.1 M OPERATING INCOME
117.19%
-57.5 M NET INCOME
31.38%
-118 M OPERATING CASH FLOW
-24.99%
114 M INVESTING CASH FLOW
315.02%
44.1 M FINANCING CASH FLOW
42.22%
Balance Sheet Alnylam Pharmaceuticals, Inc.
image
Current Assets 3.3 B
Cash & Short-Term Investments 2.69 B
Receivables 405 M
Other Current Assets 195 M
Non-Current Assets 945 M
Long-Term Investments 0
PP&E 694 M
Other Non-Current Assets 251 M
63.55 %9.56 %4.61 %16.37 %5.91 %Total Assets$4.2b
Current Liabilities 1.19 B
Accounts Payable 88.4 M
Short-Term Debt 41.9 M
Other Current Liabilities 1.06 B
Non-Current Liabilities 3.05 B
Long-Term Debt 0
Other Non-Current Liabilities 3.05 B
24.94 %71.99 %Total Liabilities$4.2b
EFFICIENCY
Earnings Waterfall Alnylam Pharmaceuticals, Inc.
image
Revenue 2.25 B
Cost Of Revenue 323 M
Gross Profit 1.92 B
Operating Expenses 2.1 B
Operating Income -177 M
Other Expenses 101 M
Net Income -278 M
3b3b2b2b2b2b1b1b500m500m00(500m)(500m)2b(323m)2b(2b)(177m)(101m)(278m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
85.62% GROSS MARGIN
85.62%
-7.87% OPERATING MARGIN
-7.87%
-12.37% NET MARGIN
-12.37%
-414.62% ROE
-414.62%
-6.47% ROA
-6.47%
-4.21% ROIC
-4.21%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Alnylam Pharmaceuticals, Inc.
image
100m100m00(100m)(100m)(200m)(200m)(300m)(300m)(400m)(400m)(500m)(500m)(600m)(600m)(700m)(700m)(800m)(800m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -278 M
Depreciation & Amortization 56.7 M
Capital Expenditures -34.3 M
Stock-Based Compensation 272 M
Change in Working Capital 0
Others 47.9 M
Free Cash Flow -42.6 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Alnylam Pharmaceuticals, Inc.
image
Wall Street analysts predict an average 1-year price target for ALNY of $304 , with forecasts ranging from a low of $235 to a high of $400 .
ALNY Lowest Price Target Wall Street Target
235 USD -14.41%
ALNY Average Price Target Wall Street Target
304 USD 10.77%
ALNY Highest Price Target Wall Street Target
400 USD 45.69%
Price
Max Price Target
Min Price Target
Average Price Target
400400350350300300250250200200150150100100Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 14
6. Ownership
Insider Ownership Alnylam Pharmaceuticals, Inc.
image
Sold
0-3 MONTHS
9.86 M USD 6
3-6 MONTHS
22.9 M USD 6
6-9 MONTHS
4.2 M USD 1
9-12 MONTHS
33.1 M USD 8
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the BofA Securities 2025 Health Care Conference on Wednesday, May 14, 2025 at 11:20 am PT (2:20 pm ET). A live audio webcast of the presentation will be available on the Investors section of the Company's website, www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after th. businesswire.com - 2 weeks ago
Alnylam Q1 Earnings Beat Estimates, Product Revenues Rise Y/Y ALNY reports better-than-expected first-quarter results as both earnings and revenues beat estimates, driven by higher product sales. zacks.com - 2 weeks ago
Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2025 Earnings Call Transcript Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Christine Lindenboom – Chief Corporate Communications Officer Yvonne Greenstreet – Chief Executive Officer Tolga Tanguler – Chief Commercial Officer Pushkal Garg – Chief Medical Officer Jeff Poulton – Chief Financial Officer Conference Call Participants Tazeen Ahmad – Bank of America Gena Wang – Barclays Teraesa Vitelli – Scotiabank Ellie Merle – UBS Gary Nachman – Raymond James Ritu Baral – TD Cowen Kostas Biliouris – BMO Capital Markets Luca Issi – RBC Capital Markets Paul Matteis – Stifel Mike Ulz – Morgan Stanley Operator Good morning ladies and gentlemen and welcome to the Alnylam Pharmaceuticals Q1 2025 Earnings Conference Call. At this time, all lines are in a listen-only mode. seekingalpha.com - 2 weeks ago
Compared to Estimates, Alnylam (ALNY) Q1 Earnings: A Look at Key Metrics While the top- and bottom-line numbers for Alnylam (ALNY) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. zacks.com - 2 weeks ago
Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates Alnylam Pharmaceuticals (ALNY) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to loss of $0.16 per share a year ago. zacks.com - 2 weeks ago
Seeking Clues to Alnylam (ALNY) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics Evaluate the expected performance of Alnylam (ALNY) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight. zacks.com - 3 weeks ago
Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of its RNAi therapeutic vutrisiran for the treatment of wild type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). ATTR-CM is a debilitating, rapidly. businesswire.com - 3 weeks ago
Earnings Preview: Alnylam Pharmaceuticals (ALNY) Q1 Earnings Expected to Decline Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 3 weeks ago
Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2025 on Thursday, May 1, 2025, before the U.S. financial markets open. Management will provide an update on the Company and discuss first quarter 2025 results as well as expectations for the future via conference call on Thursday, May 1, 2025 at 8:30 am ET. A live audio webcast of the. businesswire.com - 1 month ago
Alnylam (ALNY) Moves 8.5% Higher: Will This Strength Last? Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. zacks.com - 1 month ago
Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Needham 24th Annual Virtual Healthcare Conference on Tuesday, April 8, 2025 at 11:45 am ET. A live audio webcast of the presentation will be available on the Investors section of the Company's website, www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after the event. businesswire.com - 1 month ago
Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology's Annual Scientific Session 2025 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced moderated poster presentations of new data from the landmark HELIOS-B Phase 3 clinical trial, which evaluated vutrisiran for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM) in a population representative of today's patients. Data were presented at the American College of Cardiology's Annual Scientific Session (ACC.25) held in Chicago, Illinois. businesswire.com - 1 month ago
8. Profile Summary

Alnylam Pharmaceuticals, Inc. ALNY

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 35.7 B
Dividend Yield 0.00%
Description Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Contact 675 West Kendall Street, Cambridge, MA, 02142 https://www.alnylam.com
IPO Date June 1, 2004
Employees 2230
Officers Dr. Phillip A. Sharp Ph.D. Co-Founder, Member of the Scientific Advisory Board & Independent Director Mr. Tolga Tanguler M.B.A. Executive Vice President & Chief Commercial Officer Mr. Timothy J. Maines Chief Technical Operations & Quality Officer Dr. Kevin Joseph Fitzgerald Ph.D. Executive Vice President, Chief Scientific Officer and Head of Early Research & Early Development Ms. Christine Regan Lindenboom Chief Corporate Communications Officer Mr. Piyush Sharma J.D. Chief Ethics & Compliance Officer Mr. Robert W. Hesslein Esq., J.D. Executive Vice President, Chief Legal Officer & Corporate Secretary Dr. Yvonne L. Greenstreet M.B.A., M.D. Chief Executive Officer & Director Mr. Jeffrey V. Poulton M.B.A. Chief Financial Officer & Executive Vice President Dr. Pushkal P. Garg M.D. Chief Medical Officer and Executive Vice President of Development & Medical Affairs